A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer
- 1 August 2006
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 7 (3) , 270-277
- https://doi.org/10.3816/cbc.2006.n.040
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Chemotherapy: What Progress in the Last 5 Years?Journal of Clinical Oncology, 2005
- Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorJournal of Clinical Oncology, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- An update on epidermal growth factor receptor inhibitorsCurrent Oncology Reports, 2002
- Cell Signaling by Receptor Tyrosine KinasesPublished by Elsevier ,2000
- Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With CisplatinJournal of Clinical Oncology, 2000
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Epidermal Growth Factor Receptor Family and ChemosensitizationJNCI Journal of the National Cancer Institute, 1997
- Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal AntibodiesJNCI Journal of the National Cancer Institute, 1993